Top

Published in:

01-01-2011 | Review Article

Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder

Authors: Dr J. Antoni Ramos-Quiroga, Miguel Casas

Published in: CNS Drugs | Issue 1/2011

Abstract

Remission should be the goal of attention-deficit hyperactivity disorder (ADHD) treatment. However, there is no universally accepted definition of remission in ADHD, although clinical studies use a number of criteria. This article examines current research into the concept of remission in ADHD by reviewing the literature for definition and achievement of remission in children and adults with ADHD. Results demonstrate that the concept of remission in ADHD has been proposed by several study groups, using thresholds of validated rating scales to indicate syndromic, symptomatic and functional remission. Several studies have demonstrated the achievement of remission in ADHD children utilizing methylphenidate delivered by an osmotic, controlled-release formulation (OROS®) and atomoxetine. However, none has defined a time period over which these criteria must be met for an individual with ADHD to be considered ‘in remission’. Standardized remission criteria in ADHD will provide a tool for assessing the effectiveness of treatments for ADHD, and raise treatment standards.

Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006 Feb; 36(2): 159–65PubMed

Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007 Jun; 164(6): 942–8PubMed

Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006 Apr; 163(4): 716–23PubMedPubMedCentral

Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990 Jul; 29(4): 546–57PubMed

Barkley RA, Fischer M, Edelbrock C, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: III. Mother-child interactions, family conflicts and maternal psychopathology. J Child Psychol Psychiatry 1991 Jan; 32(2): 233–55PubMed

Gittelman R, Mannuzza S, Shenker R, et al. Hyperactive boys almost grown up: I. Psychiatric status. Arch Gen Psychiatry 1985 Oct; 42(10): 937–47PubMed

DiScala C, Lescohier I, Barthel M, et al. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998 Dec; 102(6): 1415–21PubMed

Willcutt EG, Pennington BF, Chhabildas NA, et al. Psychiatric comorbidity associated with DSM-IV ADHD in a nonreferred sample of twins. J Am Acad Child Adolesc Psychiatry 1999 Nov; 38(11): 1355–62PubMed

Biederman J, Faraone SV. The effects of attention-deficit/ hyperactivity disorder on employment and household income [abstract]. MedGenMed 2006; 8(3): 12PubMedPubMedCentral

10.

Biederman J, Petty CR, Fried R, et al. Stability of executive function deficits into young adult years: a prospective longitudinal follow-up study of grown up males with ADHD. Acta Psychiatr Scand 2007 Aug; 116(2): 129–36PubMed

11.

Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996 Dec; 98 (6 Pt 1): 1089–95PubMed

12.

Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000 Apr; 61(4): 244–51PubMed

13.

Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007 May; 190: 402–9

14.

Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006; 67(4): 524–40PubMed

15.

Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010; 19(4): 353–64PubMed

16.

Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006 Nov; 28(11): 1892–908PubMed

17.

Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry 2003; 64 Suppl. 15: 40–5PubMed

18.

Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991 Sep; 48(9): 851–5PubMed

19.

Keck Jr PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998 May; 155(5): 646–52PubMed

20.

Andreasen NC, Carpenter Jr WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005 Mar; 162(3): 441–9PubMed

21.

American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 2000

22.

Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159(11): 1896–901PubMed

23.

Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004 Jul; 114(1): e1–8PubMed

24.

Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001 Aug; 58(8): 775–82PubMed

25.

Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63(12): 1140–7PubMed

26.

Swanson JM. SNAP-IV Scale. Irvine (CA): Irvine Child Development Center, 1995

27.

DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: checklists, norms, and clinical interpretations. New York: The Guilford Press, 1998

28.

NIMH National Institute of Mental Health. Clinical Global Impression Scale. Psychopharmacol Bull 1985; 21: 839–943

29.

American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987

30.

Murphy KR, Adler LA. Assessing attention-deficit/ hyperactivity disorder in adults: focus on rating scales. J Clin Psychiatry 2004; 65 Suppl. 3: 12–7PubMed

31.

Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001 Feb; 40(2): 168–79PubMed

32.

Conners CK. Conners’ rating scales, revised. Toronto (ON): Multi-Health Systems, 1997

33.

Biederman J, Faraone S, Milberger S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996 Mar; 35(3): 343–51PubMed

34.

American Psychiatric Association. Diagnostic and statisical manual of mental disorders, 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000: 32–4

35.

Lambert NM, Hartsough CS, Sassone D, et al. Persistence of hyperactivity symptoms from childhood to adolescence and associated outcomes. Am J Orthopsychiatry 1987 Jan; 57(1): 22–32PubMed

36.

Biederman J, Mick E, Faraone SV. Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder. J Pediatr 1998 Oct; 133(4): 544–51PubMed

37.

Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms and profiles: an integrated system of multi-informant assessment. Burlington (VT): University of Vermont, Research Center for Children, Youth, and Families, 2001

38.

Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976; 33: 1111–5PubMed

39.

Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000 May; 157(5): 816–8PubMed

40.

Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006 Winter; 13(1): e50–62PubMed

41.

Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006 Nov; 45(11): 1284–93PubMed

42.

Weiss M, Wasdell M, Patin J. A post hoc analysis of D-threo-methylphenidate hydrochloride (focalin) versus D,L-threo-methylphenidate hydrochloride (ritalin). J Am Acad Child Adolesc Psychiatry 2004 Nov; 43(11): 1415–21PubMed

43.

Stein MA, Sarampote CS, Waldman ID, et al. A doseresponse study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003 Nov; 112(5): e404PubMed

44.

Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47(2): 209–18PubMed

45.

Hong H, Hong N, Yoon H, et al. Differences in the clinical characteristics of remission and non-remission groups with once-daily OROS-methylphenidate treatment of attention-deficit/hyperactivity disorder. Clin Psychopharmacol Neurosci 2008; 76(1): 24–30

46.

Guy W. ECDEU: assessment manual for psychopharmacology, revised. Rockville (MD): US Department of Health, Education and Welfare, 1976

47.

Kim YS, So YK, Choi NK, et al. Normative data on the Korean ADHD Rating Scales (K-ARS) for parents and teachers. J Korean Neuropsychiatr Assoc 2003; 42: 352–9

48.

Jacobson N, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12–9PubMed

49.

Atzori P, Usala T, Carucci S, et al. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol 2009 Dec; 19(6): 673–81PubMed

50.

Okie S. ADHD in adults. N Engl J Med 2006 Jun 22; 354(25): 2637–41PubMed

51.

Shaffer D. Attention deficit hyperactivity disorder in adults. Am J Psychiatry 1994 May; 151(5): 633–8PubMed

52.

Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the National Comorbidity Survey Replication. Biol Psychiatry 2005 Jun 1; 57(11): 1442–51PubMedPubMedCentral

53.

Andersen SL, Teicher MH. Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Biobehav Rev 2000 Jan; 24(1): 137–41PubMed

54.

Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002 May; 111(2): 279–89PubMed

55.

Anderson JC, Williams S, McGee R, et al. DSM-III disorders in preadolescent children: prevalence in a large sample from the general population. Arch Gen Psychiatry 1987 Jan; 44(1): 69–76PubMed

56.

Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico: the use of combined measures. Arch Gen Psychiatry 1988 Dec; 45(12): 1120–6PubMed

57.

Tannock R. Attention deficit hyperactivity disorder: advances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiatry 1998 Jan; 39(1): 65–99PubMed

58.

Semrud-Clikeman M, Filipek PA, Biederman J, et al. Attention-deficit hyperactivity disorder: magnetic resonance imaging morphometric analysis of the corpus callosum. J Am Acad Child Adolesc Psychiatry 1994 Jul–Aug; 33(6): 875–81PubMed

59.

Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005 Jun 1; 57(11): 1313–23PubMed

60.

Fisher SE, Francks C, McCracken JT, et al. A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am J Hum Genet 2002 May; 70(5): 1183–96PubMedPubMedCentral

61.

Bakker SC, van der Meulen EM, Buitelaar JK, et al. A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. Am J Hum Genet 2003 May; 72(5): 1251–60PubMedPubMedCentral

62.

Arcos-Burgos M, Castellanos FX, Pineda D, et al. Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p 11. Am J Hum Genet 2004 Dec; 75(6): 998–1014PubMedPubMedCentral

63.

Hebebrand J, Dempfle A, Saar K, et al. A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs. Mol Psychiatry 2006 Feb; 11(2): 196–205PubMed

64.

Ogdie MN, Bakker SC, Fisher SE, et al. Pooled genome-wide linkage data on 424 ADHD ASPs suggests genetic heterogeneity and a common risk locus at 5p 13. Mol Psychiatry 2006 Jan; 11(1): 5–8PubMed

65.

Faraone SV, Doyle AE, Lasky-Su J, et al. Linkage analysis of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008 Dec 5; 147B(8): 1387–91PubMed

66.

Asherson P, Zhou K, Anney RJ, et al. A high-density SNP linkage scan with 142 combined subtype ADHD sib pairs identifies linkage regions on chromosomes 9 and 16. Mol Psychiatry 2008 May; 13(5): 514–21PubMed

67.

Romanos M, Freitag C, Jacob C, et al. Genome-wide linkage analysis of ADHD using high-density SNP arrays: novel loci at 5q 13.1 and 14q 12. Mol Psychiatry 2008 May; 13(5): 522–30PubMed

68.

Zhou K, Dempfle A, Arcos-Burgos M, et al. Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008 Dec 5; 147B(8): 1392–8PubMedPubMedCentral

69.

Biederman J, Mick E, Faraone SV. Depression in attention deficit hyperactivity disorder (ADHD) children: “true” depression or demoralization? J Affect Disord 1998 Jan; 47(1–3): 113–22PubMed

70.

Li J, Kang C, Wang Y, et al. Contribution of 5-HT2A receptor gene −1438A>G polymorphism to outcome of attention-deficit/hyperactivity disorder in adolescents. Am J Med Genet B Neuropsychiatr Genet 2006 Jul 5; 141B(5): 473–6PubMed

71.

Li J, Kang C, Zhang H, et al. Monoamine oxidase A gene polymorphism predicts adolescent outcome of attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007 Jun 5; 144B(4): 430–3PubMed

72.

Keck Jr PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998; 155: 646–52PubMed

73.

Ribases M, Hervas A, Ramos-Quiroga JA, et al. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/ hyperactivity disorder. Biol Psychiatry 2008 May 15; 63(10): 935–45PubMed

74.

Ribases M, Ramos-Quiroga JA, Hervas A, et al. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol Psychiatry 2007; 14(1): 71–85PubMed

75.

Hamarman S, Fossella J, Ulger C, et al. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacology 2004 Winter; 14(4): 564–74

76.

Biederman J, Petty CR, Ten Haagen KS, et al. Effect of candidate gene polymorphisms on the course of attention deficit hyperactivity disorder. Psychiatry Res 2009 Dec 30; 170(2–3): 199–203PubMedPubMedCentral

77.

Schulz KP, Newcorn JH, Fan J, et al. Brain activation gradients in ventrolateral prefrontal cortex related to persistence of ADHD in adolescent boys. J Am Acad Child Adolesc Psychiatry 2005 Jan; 44(1): 47–54PubMed

78.

Shaw P, Lerch J, Greenstein D, et al. Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2006 May; 63(5): 540–9PubMed

79.

Shaffer D, Gould MS, Brasic J, et al. A Children’s Global Assessment Scale (CGAS). Arch Gen Psychiatry 1983; 40: 1228–31PubMed

80.

Mick E, Faraone S, Biederman J. Age-dependent expression of attention-deficit/hyperactivity disorder symptoms. Psychiatr Clin N Am 2004; 27: 215–24

81.

Faraone SV, Biederman J, Monuteaux MC. Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder. Genet Epidemiol 2000 Jan; 18(1): 1–16PubMed

82.

The MTA Cooperative Group. A 14-month randomised clinical trial of treatment of strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073–86

83.

Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2001 Nov; 40(11): 1352–5PubMed

84.

Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003 Feb; 60(2): 204–11PubMed

85.

Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder: first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl. 1: 17–30

86.

Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001 Jun; 107(6): e105PubMed

87.

Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Pediatr Drugs 2003; 5(12): 833–41

88.

Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003 Jan; 111(1): 179–85PubMed

89.

Rubia K, Halari R, Cubillo A, et al. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology 2009 Dec; 57(7–8): 640–52PubMed

90.

Prasad S, Steer C. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: clinical approaches and review of current available evidence. Pediatr Drugs 2008; 10(1): 39–47

91.

Bakken RJ, Paczkowski M, Kramer HP, et al. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. Curr Med Res Opin 2008 Feb; 24(2): 449–60PubMed

92.

Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008; 22(7): 603–11PubMed

93.

Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV infected patients: the GEEMA Study. AIDS 2002; 16(4): 605–13PubMed

94.

Bird HR, Gould MS, Staghezza BM. Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry 1993 Mar; 32(2): 361–8PubMed

95.

Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991 May; 148(5): 564–77PubMed

96.

Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate: a review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002 Nov; 22(8): 1107–31PubMed

97.

Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 2003 Apr; 39(3): 180–5PubMed

98.

Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005 Mar 1; 57(5): 456–63PubMed

99.

Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008; 31(4): 345–54PubMed

100.

Wernicke J, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents and adults. Drug Saf 2003; 26(10): 729–40PubMed

101.

Committee for Medicinal Products for Human Use. Questions and answers on the review of medicines containing methylphenidate [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Methylphenidate_31/WC500011125.pdf [Accessed 2010 Oct 27]

Title: Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder
Authors: Dr J. Antoni Ramos-Quiroga
Miguel Casas
Publication date: 01-01-2011
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 1/2011
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/11538450-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinson’s Disease

Interferon-β-1b

Amyotrophic Lateral Sclerosis

Oral Therapies for Multiple Sclerosis